Prestige Biopharma's PBP1510 Granted Fast Track Designation by FDA for Advanced Pancreatic Cancer Treatment

Prestige Biopharma, a leading biopharmaceutical company, has secured Fast Track designation from the U.S. Food and Drug Administration (FDA) for its innovative drug, PBP1510 (International Non-proprietary name: Ulenistamab), in the treatment of unresectable or metastatic pancreatic adenocarcinoma (PDAC) that has relapsed following and/or is refractory to at least one line of prior therapy.

Publish Date: 21-03-2023 Source: Prestige Biopharma

Pancreatic cancer (PC) is the fourth most common cancer-related cause of death in the United States. There is a scarcity of tests that facilitate early diagnosis or accurately predict the disease progression. To this end, biomarkers have been identified as important tools in the diagnosis and management of pancreatic cancer. Over the last decade, the reported incidence of pancreatic cancer was 13.1 per 100,000 men and women per year. According to the Surveillance, Epidemiology, and End Results (SEER) database, approximately 47,000 people will die due to pancreatic cancer, representing 7.8% of all cancer-related deaths, and over 55,000 new cases were expected in the United States. After diagnosis, the overall survival ranges between four and six months, with a five-year survival rate of <5%. However, survival is significantly higher in early-stage disease (IA: 31.7%; IB: 11.8%) compared to more advanced stages (IIA: 9.0%; IIB: 8.7%; III: 1.9%; IV: 0.5%.

However, the current Pancreatic Cancer treatment market share, market uptake, and attribute analysis concerning the most potential emerging therapies (SBP-101, NC-6004, etc..) has been provided under the market outlook section of the study covering 8 MM countries; The United States, EU5 (Germany, Spain, France, Italy, UK) Japan and China.

In terms of pharmacologic therapies, several pharmaceutical products are being approved and under different phases of development for the Pancreatic Cancer treatment. The key companies in the advanced development stage are Panbela Therapeutics, Inc., NanoCarrier Co., Ltd., etc..

Based on solid domain and business knowledge, Thelansis Knowledge Partners has published the market outlook forecast report on Pancreatic Cancer to provide a clear understanding of disease area background, epidemiology, current and future competitions, the country-specific standard of care, and the complete market forecast for 2021 to 2032.

About Thelansis:

Thelansis specializes in pharmaceutical market outlook and market forecast reports. We published reports across the therapeutic area, including rare / ultra-rare and mainstream indications. Over the period, we have built a robust repository of 6,000+ Bio-pharma reports that cover Epidemiology studies and Market forecasting based on the KOL opinions.

Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the primary focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.